RayKnowChina Research Map
Shortlist0

Dalian

First Affiliated Hospital of Dalian Medical University

大连医科大学附属第一医院

Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Dalian Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  2. Hepatocellular carcinoma肝细胞癌27 papers led
  3. Stomach cancer胃癌21 papers led
  4. Osteosarcoma骨肉瘤7 papers led
  5. Neuroblastoma神经母细胞瘤1 paper led
  6. Ewing sarcoma尤文肉瘤0 papers led
  7. Multiple myeloma多发性骨髓瘤5 papers led
  8. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  9. Takayasu arteritis大动脉炎0 papers led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  11. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  12. Fabry disease法布雷病0 papers led
  13. IgA nephropathyIgA 肾病1 paper led
  14. Osteogenesis imperfecta成骨不全症1 paper led
  15. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

1 hospital in Dalian for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics
Departments in papersGastroenterology / hepatologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 27 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 8820232024: 8820242025: 222025

2 hospitals in Dalian for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led27
  1. Dynamic changes of chronic hepatitis B patient with loss of surface antigen: a case report.2025BMC infectious diseasesFree full text
  2. Multidisciplinary management of concurrent small cell lung cancer and hepatocellular carcinoma: A rare case report with long-term survival.2025MedicineFree full text
  3. A rare hepatoid adenocarcinoma in the stomach of a female patient.2024Asian journal of surgery
  4. Development of an RNA modification writer-related lncRNA signature to predict prognosis, tumor microenvironment, and treatment outcome for hepatocellular carcinoma.2024Asian journal of surgery
  5. Loss of USP10 promotes hepatocellular carcinoma proliferation by regulating the serine synthesis pathway through inhibition of LKB1 activity.2024Cancer scienceFree full text
  6. Self-supervised multi-modal feature fusion for predicting early recurrence of hepatocellular carcinoma.2024Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  7. NUCB2 promotes hepatocellular carcinoma cell growth and metastasis by activating the E2F4/PTGR1 axis.2024International journal of biological sciencesFree full text
  8. Integration of network pharmacology, metabolomics and lipidomics for clarifying the role of sphingolipid metabolism in the treatment of liver cancer by regorafenib.2024Life sciences
  9. Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review).2024Molecular medicine reportsFree full text
  10. Discovering the lipid metabolism-related hub genes of HCC-treated samples with PPARα agonist through weighted correlation network analysis.2024Scientific reportsFree full text
  11. ROS in hepatocellular carcinoma: What we know.2023Archives of biochemistry and biophysics
  12. Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma.2023BMC cancerFree full text
  13. Identification of PPT1 as a lysosomal core gene with prognostic value in hepatocellular carcinoma.2023Bioscience reportsFree full text
  14. Single-cell sequencing and bulk RNA sequencing reveal a cell differentiation-related multigene panel to predict the prognosis and immunotherapy response of hepatocellular carcinoma.2023Chinese medical journalFree full text
  15. HOTAIR modulates hepatocellular carcinoma progression by activating FUT8/core-fucosylated Hsp90/MUC1/STAT3 feedback loop via JAK1/STAT3 cascade.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  16. Non‑coding RNAs: Role of miRNAs and lncRNAs in the regulation of autophagy in hepatocellular carcinoma (Review).2023Oncology reportsFree full text
  17. Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis.2023Oxidative medicine and cellular longevityFree full text
  18. A comprehensive review of the role of LINC00462 in human disorders.2023Pathology, research and practice
  19. Long non-coding RNA (lncRNA) CYTOR promotes hepatocellular carcinoma proliferation by targeting the microRNA-125a-5p/LASP1 axis.2022BioengineeredFree full text
  20. ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma.2022Bosnian journal of basic medical sciencesFree full text
  21. The role of mesenchymal stem cells in the occurrence, development, and therapy of hepatocellular carcinoma.2022Cancer medicineFree full text
  22. No differences in the risk of hepatocellular carcinoma from using direct-acting antiviral agents or interferon in patients with chronic hepatitis C: A meta-analysis.2022Clinics and research in hepatology and gastroenterology
  23. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma.2022Nature communicationsFree full text
  24. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding.2021International immunopharmacology
  25. Local anesthetic bupivacaine inhibits proliferation and metastasis of hepatocellular carcinoma cells via suppressing PI3K/Akt and MAPK signaling.2021Journal of biochemical and molecular toxicology
  26. Radiomics Analysis Based on Multiparametric MRI for Predicting Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy.2021Journal of magnetic resonance imaging : JMRI
  27. The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status4
  1. The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive TreatmentStatus unknownNCT04299919Lead sponsorStart 2007-04
  2. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  3. Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCCStatus unknownNCT04157140Study sitePhase 2Start 2019-11
  4. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 21 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
21
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 5520232024: 5520242025: 552025

2 hospitals in Dalian for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07600125

    Age 18 years to Not stated (registered criteria)

    Led by Xijing Hospital; 2 listed hospitals as study sitesDalian, Qingdao, Xi'an

  2. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopySurgeryImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led21
  1. CT-based quantification of spatiotemporal heterogeneity for predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.2025BMC medical imagingFree full text
  2. HSPA8 promotes the progression of gastric cancer by activating the canonical Wnt pathway and glycolysis.2025Human cell
  3. The impact of the age-adjusted Charlson comorbidity index as a prognostic factor in patients with early gastric cancer after endoscopic submucosal dissection.2025Scandinavian journal of gastroenterology
  4. Indocyanine Green-Guided Lymphadenectomy During Robot-Assisted Pylorus and Vagus Nerve Preserving Gastrectomy for Early Gastric Cancer: A Single-Centre Study.2025The international journal of medical robotics + computer assisted surgery : MRCAS
  5. Modified Charlson comorbidity index of long-term, non-gastric cancer mortality in patients with early gastric cancer: a multicenter retrospective study.2025World journal of surgical oncologyFree full text
  6. A rare hepatoid adenocarcinoma in the stomach of a female patient.2024Asian journal of surgery
  7. Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Endoscopic Characteristics of Early Gastroesophageal Junction Adenocarcinomas and Assessment for Invasion Depth: A Case Series Study.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  9. Clinical study of the posterior gastric artery and the lymph nodes around it in patients with gastric cancer.2024World journal of surgical oncologyFree full text
  10. Preservation of the celiac branch of the vagus nerve reduces the incidence of postoperative diarrhea in gastric cancer: a cohort study.2024World journal of surgical oncologyFree full text
  11. Oxidative stress and autophagy-mediated immune patterns and tumor microenvironment infiltration characterization in gastric cancer.2023AgingFree full text
  12. A study on metabolic characteristics and metabolic markers of gastrointestinal tumors.2023Cancer biology & therapyFree full text
  13. Discovery of a novel lipid metabolism-related gene signature to predict outcomes and the tumor immune microenvironment in gastric cancer by integrated analysis of single-cell and bulk RNA sequencing.2023Lipids in health and diseaseFree full text
  14. Fucoxanthin inhibits gastric cancer lymphangiogenesis and metastasis by regulating Ran expression.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  15. The combined signatures of the tumour microenvironment and nucleotide metabolism-related genes provide a prognostic and therapeutic biomarker for gastric cancer.2023Scientific reportsFree full text
  16. Metabolomics study identified bile acids as potential biomarkers for gastric cancer: A case control study.2022Frontiers in endocrinologyFree full text
  17. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy.2022Frontiers in immunologyFree full text
  18. The clinicopathological characteristics of gastric polyps and the relationship between fundic gland polyps, Helicobacter pylori infection, and proton pump inhibitors.2021Annals of palliative medicine
  19. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.2021Cancer medicineFree full text
  20. Cut the weeds and dig up the roots: clip-and-snare assisted endoscopic mucosal resection of a rectal neuroendocrine tumor.2021Endoscopy
  21. MicroRNA-936/ERBB4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion.2021The Kaohsiung journal of medical sciencesFree full text
Chinese-language papers (not in the count)4
  1. [Scleromitrion diffusum reverses epithelial-mesenchymal transi-tion of gastric mucosa in rats with gastric precancerous lesions].2025Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciencesFree full text
  2. [Research progress of function-preserving surgery for gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Clinical significance of laparoscopic and endoscopic cooperative surgery in function preserving gastrectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Da Vinci robot-assisted pylorus and vagus nerve-preserving partial gastrectomy for gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status5
  1. Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern TherapyStatus unknownNCT04215861Lead sponsorStart 2019-10
  2. The Clinical Study of Adjuvant Chemotherapy on Intestinal and Urethral Flora in Patients With Gastric and Colon CancerStatus unknownNCT04198051Lead sponsorN/AStart 2019-12
  3. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  4. Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract CancersRecruitingNCT07600125Study siteStart 2026-08
  5. A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric CancerTerminatedNCT01967875Study sitePhase 2Start 2013-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 3320242025: 002025

8 hospitals in Dalian for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led7
  1. The lung pre-metastatic niche in osteosarcoma: Mechanism and therapeutic intervention.2026International journal of cancer
  2. Maf proteins-based predictive model for the prognosis of osteosarcoma.2024Asian journal of surgery
  3. Comprehensive analysis of NT5DC family-based prognostic model in osteosarcoma.2024Asian journal of surgery
  4. Integrated analysis of single-cell and bulk RNA sequencing data reveals prognostic characteristics of lysosome-dependent cell death-related genes in osteosarcoma.2024BMC genomics
  5. A novel alternative splicing-related prognostic signature for osteosarcoma.2023Asian journal of surgery
  6. A prognostic model based on the integrin genes for osteosarcoma.2023Asian journal of surgery
  7. LncRNA ZFAS1 contributes to osteosarcoma progression via miR-520b and miR-520e-mediated inhibition of RHOC signaling.2023Clinics (Sao Paulo, Brazil)
Earlier papers (2016–2020)5
  1. Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma.2018Molecular cancer
  2. Long non-coding RNA TUG1 promotes migration and invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells.2017Cancer science
  3. PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration.2017Oncotarget
  4. Potential approaches to the treatment of Ewing's sarcoma.2017Oncotarget
  5. Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.2016Cancer letters

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Dalian for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Dalian for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Potential approaches to the treatment of Ewing's sarcoma.2017Oncotarget

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 222025

1 hospital in Dalian for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugsDrug combinations
Departments in papersPathology / laboratory medicineRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Dalian for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Dalian for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Carotid contrast-enhanced ultrasonographic assessment of disease activity in Takayasu arteritis.2019European heart journal. Cardiovascular Imaging

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

3 hospitals in Dalian for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Dalian for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Dalian for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Coexistence of Fabry Disease and Membranous Nephropathy.2016Iranian journal of kidney diseases

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Dalian for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Positive association of serum FUT8 activity with renal tubulointerstitial injury in IgA nephropathy patients.2022Immunity, inflammation and disease
Earlier papers (2016–2020)1
  1. Novel Mechanism of the Pericyte-Myofibroblast Transition in Renal Interstitial Fibrosis: Core Fucosylation Regulation.2017Scientific reports
All its trials on ClinicalTrials.gov, any status3
  1. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  2. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  3. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Dalian for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Dalian for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

大连医科大学附属第一医院

First Affiliated Hospital of Dalian Medical University

大连

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First affiliated hospital of Dalian Medical University

Suggest a correctionDownload the data